630 related articles for article (PubMed ID: 23686416)
1. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
3. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
[TBL] [Abstract][Full Text] [Related]
4. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.
Yao W; Feng D; Bian W; Yang L; Li Y; Yang Z; Xiong Y; Zheng J; Zhai R; He J
Amino Acids; 2012 Nov; 43(5):2027-35. PubMed ID: 22476347
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
[TBL] [Abstract][Full Text] [Related]
6. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells.
Song RX; Zhang Z; Chen Y; Bao Y; Santen RJ
Endocrinology; 2007 Aug; 148(8):4091-101. PubMed ID: 17525128
[TBL] [Abstract][Full Text] [Related]
7. The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.
Kirkegaard T; Yde CW; Kveiborg M; Lykkesfeldt AE
Int J Oncol; 2014 Jul; 45(1):393-400. PubMed ID: 24819550
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
9. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
10. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
11. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
13. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
14. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
15. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
[TBL] [Abstract][Full Text] [Related]
16. Proximal events in signaling by plasma membrane estrogen receptors.
Razandi M; Pedram A; Park ST; Levin ER
J Biol Chem; 2003 Jan; 278(4):2701-12. PubMed ID: 12421825
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
Hutcheson IR; Goddard L; Barrow D; McClelland RA; Francies HE; Knowlden JM; Nicholson RI; Gee JM
Breast Cancer Res; 2011 Mar; 13(2):R29. PubMed ID: 21396094
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks.
Banerjee S; Sengupta K; Saxena NK; Dhar K; Banerjee SK
Mol Cancer Res; 2005 Mar; 3(3):151-62. PubMed ID: 15798095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
